Cancer diagnostics darling Foundation Medicine released its first quarterly numbers as a public company, and they show encouraging revenue gains as the Massachusetts outfit pursued a rapid sales expansion for its debut product.
Last year when we did the list of the top 10 biotech IPOs of 2012, we were lucky to have 10. Actually, there were 11, and that looked pretty good compared to the lean and hungry years of 2008 to...
Despite renewed investor fervor and no shortage of promising technologies, medical device outfits had so far been largely loathe to join in on the biotech IPO revival. Now that LDR has bagged an over-allotted, top-of-its range debut, is it time for med tech's big moment?
Cancer diagnostics darling Foundation Medicine stock closed at $35.35 on its first day of trading, which Dow Jones noted was a whopping 96% higher than the debut price of $18 per share.
Diagnostics wunderkind Foundation Medicine has made its way to the Nasdaq, hauling in a $106 million IPO at the top of its range.
Any jitters about investors' appetite for new biotech IPOs were set aside--at least temporarily--after a trio of companies pushed their way confidently into the market yesterday, raising about $300 million.
Analysts will be watching closely to see if a series of recent stumbles out of the gate are the result of individual problems or an example of a growing lack of the kind of ravenous appetite that drove a 6-month feast of offerings.
Diagnostics outfit Foundation Medicine is hopping on the IPO bandwagon. It said it plans to raise $75 million by offering 5 million shares at a price range of $14 to $16.
Diagnostics luminary Foundation Medicine is looking to cash in on the burgeoning IPO trend, ticking up the top of its expected haul to $92 million.
Foundation Medicine unveiled plans this week for an $86.3 million IPO, the latest milestone in what has already been a rapid rise for a Cambridge, MA, diagnostics startup that's only a few years old.